Chardan Capital upgraded shares of Krystal Biotech (NASDAQ:KRYS – Free Report) to a strong-buy rating in a research report released on Monday,Zacks.com reports.
Other research analysts also recently issued reports about the company. Jefferies Financial Group restated a “buy” rating and set a $474.00 target price on shares of Krystal Biotech in a research note on Monday, July 13th. TD Cowen raised their price target on Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. Bank of America boosted their price target on Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Citigroup increased their price objective on shares of Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Evercore reiterated an “outperform” rating and issued a $300.00 target price on shares of Krystal Biotech in a research note on Tuesday, May 5th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $361.56.
View Our Latest Report on KRYS
Krystal Biotech Stock Performance
Krystal Biotech (NASDAQ:KRYS – Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, beating the consensus estimate of $1.70 by $0.09. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. The company had revenue of $119.22 million during the quarter, compared to the consensus estimate of $120.93 million. As a group, equities analysts predict that Krystal Biotech will post 7.27 earnings per share for the current fiscal year.
Insider Activity at Krystal Biotech
In related news, EVP John Charles Thomas sold 1,000 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the completion of the transaction, the executive vice president owned 1,000 shares of the company’s stock, valued at $347,270. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the sale, the insider directly owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 26,642 shares of company stock worth $8,243,923. 13.10% of the stock is owned by corporate insiders.
Institutional Trading of Krystal Biotech
A number of hedge funds have recently modified their holdings of KRYS. Avoro Capital Advisors LLC raised its position in Krystal Biotech by 4.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,888,888 shares of the company’s stock valued at $712,226,000 after acquiring an additional 111,111 shares in the last quarter. State Street Corp increased its holdings in shares of Krystal Biotech by 10.5% during the 2nd quarter. State Street Corp now owns 1,355,346 shares of the company’s stock valued at $186,306,000 after purchasing an additional 128,639 shares in the last quarter. Soleus Capital Management L.P. lifted its stake in shares of Krystal Biotech by 108.9% in the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after purchasing an additional 481,200 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Krystal Biotech by 5.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 533,964 shares of the company’s stock valued at $94,261,000 after purchasing an additional 28,075 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Krystal Biotech by 13.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 529,955 shares of the company’s stock worth $130,656,000 after buying an additional 62,897 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.
About Krystal Biotech
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
Featured Articles
- Five stocks we like better than Krystal Biotech
- These Outperforming Giants Are Boosting Dividends in 2026, With Yields of Up to 6.6%
- Why Analysts Are Bullish on a Stock That’s Down 20%
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
